CYP19A1 and breast carcinoma: Obese breast cancer patients have a worse outcome and do not respond well to aromatase inhibitor treatment and chemotherapy which may be linked to elevated COX-2 expression and the prostaglandin E2 (PGE2) (Subbaramaiah et al., 2012; Bowers and DeGraffenried, 2015).